A recent article published in the August, 2013 edition of Hepatology by CH Chang et al. titled “Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus” studied the connection between certain diabetes drugs and cancer. Thiazolidinediones are a class of diabetes drugs including Actos and others.
This team of researchers wrote “The objective of this nationwide case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs)” and studied a total of 606,583 patients with type II diabetes without a history of cancer.
“A total of 10,741 liver cancer cases, 7,200 colorectal cancer cases, and 70,559 diabetic controls were included. A significantly lower risk of liver cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively.” This means that Actos (pioglitazone) was associated with a lower risk for liver cancer, and so was Avandia (rosiglitazone).
However, the team found that “a potential increased risk for bladder cancer with pioglitazone use 3 years could not be excluded (OR: 1.56; 95% CI: 0.51-4.74),” meaning that Actos was associated with a 56% increased risk for bladder cancer.
Due to the fact that a number of people have used Actos unaware of the risk for bladder cancer, a number of Actos bladder cancer lawsuits have been filed. If you or a loved one used Actos and suffered bladder cancer, contact our team of Actos bladder cancer lawyers for a free consultation at the information provided below. You and your family may be entitled to significant financial compensation, and we have the experience, resources, and skills required to win the justice you deserve.
(855) 452 – 5529